3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
CNS
3
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
3
entrectinib
2
Radiotherapy
2
Proton Therapy
2
Fluorodeoxyglucose F18
2
FAPI-46
2
tipifarnib
1
pegvisomant
1
fluorodopa F 18
1
entinostat
1
dactolisib
1
alectinib
1
Trastuzumab
1
Tamoxifen
1
Surveys and Questionnaires
1
Specimen Handling
1
Ritonavir
1
Respiratory Therapy
1
Radiation Dose Hypofractionation
1
Quality of Life
1
Protons
1
Positron-Emission Tomography
1
Photochemotherapy
1
Patient Reported Outcome Measures
1
Octreotide
1
Neuropsychological Tests
1
Molecular Diagnostic Techniques
1
Indinavir
1
Immunotherapy
1
Furosemide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
alectinib
×
Endocrine
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts